Frontage expands US–China clinical footprint to meet demand for early phase integration
Frontage Laboratories expands US and China early phase clinical sites with radiolabel, BE, and oncology focus. Find out what this means for CRDMOs in 2026.
Pharma & Biotech
Pharma & Biotech
How Brazil’s GMP approval for pembrolizumab biosimilar changes global biosimilar dynamics
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.